LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Collision diffuse large B cell lymphoma and myeloid sarcoma in the liver.

    Marra, Andrea / Martino, Giovanni / Scarpelli, Nando / Perriello, Vincenzo / Limongello, Roberto / Ascani, Stefano

    Annals of hematology

    2020  Volume 100, Issue 10, Page(s) 2649–2651

    MeSH term(s) Aged ; Female ; Humans ; Liver/pathology ; Liver Neoplasms/complications ; Liver Neoplasms/pathology ; Lymphoma, Large B-Cell, Diffuse/complications ; Lymphoma, Large B-Cell, Diffuse/pathology ; Sarcoma, Myeloid/complications ; Sarcoma, Myeloid/pathology
    Language English
    Publishing date 2020-08-28
    Publishing country Germany
    Document type Case Reports ; Letter
    ZDB-ID 1064950-5
    ISSN 1432-0584 ; 0939-5555 ; 0945-8077
    ISSN (online) 1432-0584
    ISSN 0939-5555 ; 0945-8077
    DOI 10.1007/s00277-020-04224-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.181: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.

    Limongello, Roberto / Marra, Andrea / Mancusi, Antonella / Bonato, Samanta / Hoxha, Eni / Ruggeri, Loredana / Hui, Susanta / Velardi, Andrea / Pierini, Antonio

    Frontiers in immunology

    2021  Volume 12, Page(s) 695051

    Abstract: Adverse genetic risk acute myeloid leukemia (AML) includes a wide range of clinical-pathological entities with extremely poor outcomes; thus, novel therapeutic approaches are needed. Promising results achieved by engineered chimeric antigen receptor (CAR) ...

    Abstract Adverse genetic risk acute myeloid leukemia (AML) includes a wide range of clinical-pathological entities with extremely poor outcomes; thus, novel therapeutic approaches are needed. Promising results achieved by engineered chimeric antigen receptor (CAR) T cells in other blood neoplasms have paved the way for the development of immune cell-based therapies for adverse genetic risk AML. Among these, adoptive cell immunotherapies with single/multiple CAR-T cells, CAR-natural killer (NK) cells, cytokine-induced killer cells (CIK), and NK cells are subjects of ongoing clinical trials. On the other hand, allogeneic hematopoietic stem cell transplantation (allo-HSCT) still represents the only curative option for adverse genetic risk AML patients. Unfortunately, high relapse rates (above 50%) and associated dismal outcomes (reported survival ~10-20%) even question the role of current allo-HSCT protocols and emphasize the urgency of adopting novel effective transplant strategies. We have recently demonstrated that haploidentical allo-HSCT combined with regulatory and conventional T cells adoptive immunotherapy (Treg-Tcon haplo-HSCT) is able to overcome disease-intrinsic chemoresistance, prevent leukemia-relapse, and improve survival of adverse genetic risk AML patients. In this
    MeSH term(s) Biomarkers, Tumor/genetics ; Cytokine-Induced Killer Cells/immunology ; Cytokine-Induced Killer Cells/transplantation ; Diffusion of Innovation ; Genetic Predisposition to Disease ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/mortality ; Killer Cells, Natural/immunology ; Killer Cells, Natural/transplantation ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/immunology ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/therapy ; Mutation ; Phenotype ; Receptors, Chimeric Antigen/genetics ; Risk Assessment ; Risk Factors ; T-Lymphocytes/immunology ; T-Lymphocytes/transplantation ; Time Factors ; Treatment Outcome
    Chemical Substances Biomarkers, Tumor ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2021-08-03
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.695051
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma.

    Venanzi, Alessandra / Marra, Andrea / Schiavoni, Gianluca / Milner, Sara G / Limongello, Roberto / Santi, Alessia / Pettirossi, Valentina / Ultimo, Simona / Tasselli, Luisa / Pucciarini, Alessandra / Falini, Lorenza / Sciabolacci, Sofia / Martelli, Maria Paola / Sportoletti, Paolo / Ascani, Stefano / Falini, Brunangelo / Tiacci, Enrico

    Cancer discovery

    2021  Volume 2, Issue 3, Page(s) 216–225

    Abstract: Clonal hematopoiesis predisposes to hematologic malignancies. However, clonal hematopoiesis is understudied in classic Hodgkin lymphoma (cHL), a mature B-cell neoplasm exhibiting the most abundant microenvironment. We analyzed clonal hematopoiesis in 40 ... ...

    Abstract Clonal hematopoiesis predisposes to hematologic malignancies. However, clonal hematopoiesis is understudied in classic Hodgkin lymphoma (cHL), a mature B-cell neoplasm exhibiting the most abundant microenvironment. We analyzed clonal hematopoiesis in 40 cHL cases by sequencing microdissected tumor cells and matched normal cells from blood and/or lymph nodes. Five patients had blood and/or tissue clonal hematopoiesis. In three of five patients (all failing first-line therapy), clonal hematopoiesis spread through the tissue microenvironment extensively, and featured mutant
    Language English
    Publishing date 2021-04-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2643-3230.BCD-20-0203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients.

    Venanzi, Alessandra / Marra, Andrea / Schiavoni, Gianluca / Milner, Sara G / Limongello, Roberto / Santi, Alessia / Pettirossi, Valentina / Ultimo, Simona / Tasselli, Luisa / Pucciarini, Alessandra / Falini, Lorenza / Sciabolacci, Sofia / Martelli, Maria Paola / Sportoletti, Paolo / Ascani, Stefano / Falini, Brunangelo / Tiacci, Enrico

    Blood cancer discovery

    2021  Volume 2, Issue 3, Page(s) 216–225

    Abstract: Clonal hematopoiesis predisposes to hematological malignancies. However, clonal hematopoiesis is understudied in classical Hodgkin lymphoma (cHL), a mature B-cell neoplasm exhibiting the most abundant microenvironment. We analyzed clonal hematopoiesis in ...

    Abstract Clonal hematopoiesis predisposes to hematological malignancies. However, clonal hematopoiesis is understudied in classical Hodgkin lymphoma (cHL), a mature B-cell neoplasm exhibiting the most abundant microenvironment. We analyzed clonal hematopoiesis in 40 cHL cases by sequencing microdissected tumor cells and matched normal cells from blood and/or lymph nodes. Five patients had blood and/or tissue clonal hematopoiesis. In three of five patients (all failing first-line therapy), clonal hematopoiesis spread through the tissue microenvironment extensively, and featured mutant
    MeSH term(s) Clonal Hematopoiesis/genetics ; Epstein-Barr Virus Infections ; Herpesvirus 4, Human ; Hodgkin Disease/genetics ; Humans ; Mutation ; Tumor Microenvironment
    Language English
    Publishing date 2021-04-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3028898-8
    ISSN 2643-3249 ; 2643-3230
    ISSN (online) 2643-3249
    ISSN 2643-3230
    DOI 10.1158/2643-3230.BCD-20-0203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Richter's transformation in the heart.

    Marra, Andrea / Adamo, Francesco / Baldoni, Stefano / Laurenti, Maria Elena / Giansanti, Michele / Pasquino, Stefano / Bigerna, Barbara / Sorcini, Daniele / Stella, Arianna / Guarente, Valerio / Limongello, Roberto / Perriello, Vincenzo / Martino, Giovanni / Ascani, Stefano / Falini, Brunangelo / Sportoletti, Paolo

    The Lancet. Oncology

    2021  Volume 22, Issue 7, Page(s) e341

    MeSH term(s) Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/genetics ; Cardiac Surgical Procedures ; Cell Transformation, Neoplastic/genetics ; Cell Transformation, Neoplastic/immunology ; Cell Transformation, Neoplastic/pathology ; Diagnosis, Differential ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Lymphoma, Large B-Cell, Diffuse/therapy ; Myocardium/immunology ; Myocardium/pathology ; Predictive Value of Tests ; Treatment Outcome
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2021-06-29
    Publishing country England
    Document type Case Reports ; Research Support, Non-U.S. Gov't
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(21)00153-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia.

    Pierini, Antonio / Ruggeri, Loredana / Carotti, Alessandra / Falzetti, Franca / Saldi, Simonetta / Terenzi, Adelmo / Zucchetti, Claudio / Ingrosso, Gianluca / Zei, Tiziana / Iacucci Ostini, Roberta / Piccinelli, Sara / Bonato, Samanta / Tricarico, Sara / Mancusi, Antonella / Ciardelli, Sara / Limongello, Roberto / Merluzzi, Mara / Di Ianni, Mauro / Tognellini, Rita /
    Minelli, Olivia / Mecucci, Cristina / Martelli, Maria Paola / Falini, Brunangelo / Martelli, Massimo Fabrizio / Aristei, Cynthia / Velardi, Andrea

    Blood advances

    2021  Volume 5, Issue 5, Page(s) 1199–1208

    Abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel HLA-haploidentical HSCT protocol that addressed the 2 remaining major ... ...

    Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel HLA-haploidentical HSCT protocol that addressed the 2 remaining major unmet medical needs: leukemia relapse and chronic graft-versus-host disease (cGVHD). Fifty AML patients were enrolled in the study. The conditioning regimen included total body irradiation for patients up to age 50 years and total marrow/lymphoid irradiation for patients age 51 to 65 years. Irradiation was followed by thiotepa, fludarabine, and cyclophosphamide. Patients received an infusion of 2 × 106/kg donor regulatory T cells on day -4 followed by 1 × 106/kg donor conventional T cells on day -1 and a mean of 10.7 × 106 ± 3.4 × 106/kgpurified CD34+ hematopoietic progenitor cells on day 0. No pharmacological GVHD prophylaxis was administered posttransplantation. Patients achieved full donor-type engraftment. Fifteen patients developed grade ≥2 acute GVHD (aGVHD). Twelve of the 15 patients with aGVHD were alive and no longer receiving immunosuppressive therapy. Moderate/severe cGVHD occurred in only 1 patient. Nonrelapse mortality occurred in 10 patients. Only 2 patients relapsed. Consequently, at a median follow-up of 29 months, the probability of moderate/severe cGVHD/relapse-free survival was 75% (95% confidence interval, 71%-78%). A novel HLA-haploidentical HSCT strategy that combines an age-adapted myeloablative conditioning regimen with regulatory and conventional T-cell adoptive immunotherapy resulted in an unprecedented cGVHD/relapse-free survival rate in 50 AML patients with a median age of 53 years. This trial was registered with the Umbria Region Institutional Review Board Public Registry as identification code 02/14 and public registry #2384/14 and at www.clinicaltrials.gov as #NCT03977103.
    MeSH term(s) Aged ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute/therapy ; Middle Aged ; Transplantation Conditioning ; Whole-Body Irradiation
    Language English
    Publishing date 2021-01-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2020003739
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: NCOA4 transcriptional coactivator inhibits activation of DNA replication origins.

    Bellelli, Roberto / Castellone, Maria Domenica / Guida, Teresa / Limongello, Roberto / Dathan, Nina Alayne / Merolla, Francesco / Cirafici, Anna Maria / Affuso, Andrea / Masai, Hisao / Costanzo, Vincenzo / Grieco, Domenico / Fusco, Alfredo / Santoro, Massimo / Carlomagno, Francesca

    Molecular cell

    2014  Volume 55, Issue 1, Page(s) 123–137

    Abstract: NCOA4 is a transcriptional coactivator of nuclear hormone receptors that undergoes gene rearrangement in human cancer. By combining studies in Xenopus laevis egg extracts and mouse embryonic fibroblasts (MEFs), we show here that NCOA4 is a minichromosome ...

    Abstract NCOA4 is a transcriptional coactivator of nuclear hormone receptors that undergoes gene rearrangement in human cancer. By combining studies in Xenopus laevis egg extracts and mouse embryonic fibroblasts (MEFs), we show here that NCOA4 is a minichromosome maintenance 7 (MCM7)-interacting protein that is able to control DNA replication. Depletion-reconstitution experiments in Xenopus laevis egg extracts indicate that NCOA4 acts as an inhibitor of DNA replication origin activation by regulating CMG (CDC45/MCM2-7/GINS) helicase. NCOA4(-/-) MEFs display unscheduled origin activation and reduced interorigin distance; this results in replication stress, as shown by the presence of fork stalling, reduction of fork speed, and premature senescence. Together, our findings indicate that NCOA4 acts as a regulator of DNA replication origins that helps prevent inappropriate DNA synthesis and replication stress.
    MeSH term(s) Animals ; Cells, Cultured ; Cellular Senescence ; DNA Replication ; HeLa Cells ; Humans ; Mice ; Minichromosome Maintenance Complex Component 7/metabolism ; Nuclear Receptor Coactivators/metabolism ; Nuclear Receptor Coactivators/physiology ; Replication Origin ; Two-Hybrid System Techniques ; Xenopus laevis
    Chemical Substances NCOA4 protein, human ; NcoA4 protein, mouse ; Nuclear Receptor Coactivators ; MCM7 protein, human (EC 3.6.4.12) ; Minichromosome Maintenance Complex Component 7 (EC 3.6.4.12)
    Language English
    Publishing date 2014-07-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1415236-8
    ISSN 1097-4164 ; 1097-2765
    ISSN (online) 1097-4164
    ISSN 1097-2765
    DOI 10.1016/j.molcel.2014.04.031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5055: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top